Coronavirus: Vaccination

(asked on 4th June 2021) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) assess the effectiveness of covid-19 vaccines for people with blood cancer and (b) establish a testing programme to clarify whether people with blood cancer retain compromised immune systems against covid-19 even after vaccination.


Answered by
Nadhim Zahawi Portrait
Nadhim Zahawi
This question was answered on 29th June 2021

All of the currently authorised COVID-19 vaccines are suitable for use in immunocompromised individuals, including those with blood cancer. The clinical studies for these vaccines excluded immunocompromised subjects and therefore no data is currently available regarding the use of these vaccines when used at the same time as immunosuppressant medicines or the immune response in those on such medications. However, data is being collected on use of the vaccines in immunocompromised subjects and the Medicines and Healthcare products Regulatory Agency will assess this data as soon as it become available. Public Health England is also monitoring the impact of COVID-19 vaccines on a broad range of outcomes including symptomatic disease, infection and hospitalisations as set out in the vaccine surveillance strategy, including protection in different clinical risk groups.

Reticulating Splines